🔗 Share this article

Given that America proceeds with unprecedented changes to its vaccine schedules, one figure appears in a surprising turn: Høeg, an American of Danish descent sports physician and public health researcher who initially gained attention by questioning Covid vaccinations during the pandemic and has zeroed in on alleged fatalities after Covid immunization in her recent time at the Food and Drug Administration.

Proposed Overhauls to Pediatric Vaccine Schedule

Agency leaders were set to announce sweeping changes to the childhood immunization program in December, aligning the US with Denmark’s immunization schedule, it is understood – a major change that would put the US out of alignment with much of the world with insufficient data for benefit. This reveal has been postponed until the next year.

Rather than the director of the vaccine center, Tracy Beth Høeg is listed to present at the gathering. She was newly appointed interim head of the FDA’s CDER, the fifth person to run the division this calendar year.

A New Direction at the Agency

The acting appointment could signify a strengthened alliance between the pharmaceutical and biologics divisions as Høeg and Prasad strengthen their influence at the regulatory agency – and it points to a increased emphasis upon dismantling previously authorized vaccines at the FDA.

Dr. Høeg has frequently advocated for ending some childhood vaccine recommendations in the US so as to align more like Denmark, a country with nationalized medicine and a population approximately the population of Wisconsin’s.

So far statements, she has persisted in emphasizing on vaccines – typically the domain of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Questions Over Qualifications

The appointee has no obvious track record in pharmaceutical research, oversight or management, which has been customary for previous heads of the CBER. She has served at the FDA as a key advisor to the agency head and CBER since earlier this year.

“It seems she lacks to have the necessary background” for overseeing the drug-regulation department, stated Jonathan Howard. “She’s never run a clinical trial. She is not versed in leading a sizeable institution. She is not an expert in industry regulation.”

Former commissioners of CBER would “be deeply familiar with laws and regulations and the research of drug development”, said Dr. Janet Woodcock. “Frankly, she lacks the type of experience that previous people who led the center have had.”

The drug center has an immense portfolio at the agency, she stated.

“Everybody just focuses on the novel medication approvals, but the generic program approves a multitude of generic drugs. There is also a biologic copycat branch, OTC medication office and other areas, and all of those have to be supervised,” Dr. Woodcock explained. “The responsibility you overlook, that is the part that I always told people is going to come back to haunt you.”

There is also, a substantial management element to the job, which supervises over 5,000 employees. “It is a huge leadership role, if you execute it properly,” Woodcock concluded.

Response and Disputed Policies

In response to concerns about Dr. Høeg's qualifications and whether this appointment represents increased cooperation among agency officials on immunizations, a press secretary said that the “questions are based on inaccurate presumptions”.

“Her experience is consistent with the functions of her job,” the official said, noting the time Høeg spent guiding the agency head on “pharmaceutical safety and oversight research, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg takes over the agency head's new expedited review system, a disputed one-day medication authorization process that reportedly concerned her preceding directors. “By what process are these medications being picked for this fast-track system? Who is making the choices?” Howard questioned. “There’s a lot of lack of transparency occurring at the FDA right now.”

Overall, he remarked, “the FDA appears to be shifting towards more relaxed regulations of all drugs, except for immunizations.”

Documented Track Record on Immunizations

Concerning immunizations, Dr. Høeg has a more established, if concerning, track record, some experts observe. She released a study using non-validated volunteer-provided data to determine the incidence of heart inflammation following COVID-19 immunization. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who allegedly have modified findings to suggest Covid vaccines are more dangerous than they are.

Included in her “policy goals” for the new government included changing guidelines for new vaccines and halting “non-essential” immunizations, she remarked following the vote on a podcast. At the agency, Høeg has allegedly proposed preventing adolescent males from receiving Covid vaccinations.

“She is an all-around dogmatist who starts off with her beliefs and works backwards to fit the data in a extremely disingenuous, fraudulent way,” Dr. Howard said.

Consolidating Power and a “Campaign of Retribution”

Høeg joined other contrarians, {like|